Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.


Journal

Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 19 3 2019
pubmed: 19 3 2019
medline: 12 9 2020
Statut: ppublish

Résumé

Cognitive rehabilitation (CR) is an individualised, person-centred intervention for people with mild to moderate dementia that addresses the impact of cognitive impairment on everyday functioning. To determine whether or not CR is a clinically effective and cost-effective intervention for people with mild to moderate Alzheimer's disease or vascular or mixed dementia, and their carers. This multicentre randomised controlled trial compared CR with treatment as usual (TAU). Following a baseline assessment and goal-setting to identify areas of everyday functioning that could be improved or better managed, participants were randomised (1 : 1) via secure web access to an independent randomisation centre to receive either TAU or CR and followed up at 3 and 9 months post randomisation. Community. Participants had an Cognitive rehabilitation consisted of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months, delivered in participants' homes. The therapists were nine occupational therapists and one nurse. The primary outcome was self-reported goal attainment at 3 months. Goal attainment was also assessed at 9 months. Carers provided independent ratings of goal attainment at both time points. The secondary outcomes were participant quality of life, mood, self-efficacy and cognition, and carer stress, health status and quality of life. The assessments at 3 and 9 months were conducted by researchers who were blind to the participants' group allocation. A total of 475 participants were randomised (CR arm, Possible limitations arose from the non-feasibility of using observational outcome measures, the lack of a general measure of functional ability and the exclusion of people without a carer or with rarer forms of dementia. Cognitive rehabilitation is clinically effective in enabling people with early-stage dementia to improve their everyday functioning in relation to individual goals targeted in the therapy sessions. Next steps will focus on the implementation of CR into NHS and social care services and on extending the approach to people with rarer forms of dementia. Current Controlled Trials ISRCTN21027481. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Cognitive rehabilitation (CR) is a personalised intervention to help people with early-stage dementia to manage everyday activities. This individualised therapy is conducted in people’s own homes over several sessions. A therapist works with the person and the carer to identify realistic and relevant goals, plan how to tackle these and support people in achieving them. Previous small studies suggested that CR could be beneficial. The Goal-oriented cognitive Rehabilitation in Early-stage Alzheimer’s and related dementias: multicentre single-blind randomised controlled Trial (GREAT) was run in eight centres to find out whether or not CR improves everyday functioning. Participants were in the early stages of having Alzheimer’s disease, vascular dementia or mixed dementia, with a family carer involved. At the first assessment, participants identified areas in which they would like to see improvements, and set goals. Participants and carers rated how well participants were currently doing in relation to these goals and completed questionnaires, for example about mood and quality of life. Participants were then randomly selected to either receive CR or continue with treatment as usual (TAU). CR consisted of 10 weekly sessions with the therapist over 3 months, followed by four sessions over the next 6 months. Participants were reassessed after 3 and 9 months. We included 475 participants, and 427 participants (90%) completed the trial (209 participants in the CR arm and 218 participants in the TAU arm). After 3 months, the ratings by both participants and carers in the CR group showed that participants were doing significantly better in relation to their goals, and this was maintained 6 months later. Ratings for the TAU-arm participants did not improve significantly. There were no other differences between the groups. There was a strong economic case for CR. Cognitive rehabilitation is effective in enabling people with early-stage dementia to improve their everyday functioning in relation to individual goals targeted in the therapy sessions. Next steps will focus on the implementation of CR into NHS and social care services.

Sections du résumé

BACKGROUND
Cognitive rehabilitation (CR) is an individualised, person-centred intervention for people with mild to moderate dementia that addresses the impact of cognitive impairment on everyday functioning.
OBJECTIVES
To determine whether or not CR is a clinically effective and cost-effective intervention for people with mild to moderate Alzheimer's disease or vascular or mixed dementia, and their carers.
DESIGN
This multicentre randomised controlled trial compared CR with treatment as usual (TAU). Following a baseline assessment and goal-setting to identify areas of everyday functioning that could be improved or better managed, participants were randomised (1 : 1) via secure web access to an independent randomisation centre to receive either TAU or CR and followed up at 3 and 9 months post randomisation.
SETTING
Community.
PARTICIPANTS
Participants had an
INTERVENTION
Cognitive rehabilitation consisted of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months, delivered in participants' homes. The therapists were nine occupational therapists and one nurse.
OUTCOME MEASURES
The primary outcome was self-reported goal attainment at 3 months. Goal attainment was also assessed at 9 months. Carers provided independent ratings of goal attainment at both time points. The secondary outcomes were participant quality of life, mood, self-efficacy and cognition, and carer stress, health status and quality of life. The assessments at 3 and 9 months were conducted by researchers who were blind to the participants' group allocation.
RESULTS
A total of 475 participants were randomised (CR arm,
LIMITATIONS
Possible limitations arose from the non-feasibility of using observational outcome measures, the lack of a general measure of functional ability and the exclusion of people without a carer or with rarer forms of dementia.
CONCLUSIONS
Cognitive rehabilitation is clinically effective in enabling people with early-stage dementia to improve their everyday functioning in relation to individual goals targeted in the therapy sessions.
FUTURE WORK
Next steps will focus on the implementation of CR into NHS and social care services and on extending the approach to people with rarer forms of dementia.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN21027481.
FUNDING
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
BACKGROUND
Cognitive rehabilitation (CR) is a personalised intervention to help people with early-stage dementia to manage everyday activities. This individualised therapy is conducted in people’s own homes over several sessions. A therapist works with the person and the carer to identify realistic and relevant goals, plan how to tackle these and support people in achieving them. Previous small studies suggested that CR could be beneficial.
METHODS
The Goal-oriented cognitive Rehabilitation in Early-stage Alzheimer’s and related dementias: multicentre single-blind randomised controlled Trial (GREAT) was run in eight centres to find out whether or not CR improves everyday functioning. Participants were in the early stages of having Alzheimer’s disease, vascular dementia or mixed dementia, with a family carer involved. At the first assessment, participants identified areas in which they would like to see improvements, and set goals. Participants and carers rated how well participants were currently doing in relation to these goals and completed questionnaires, for example about mood and quality of life. Participants were then randomly selected to either receive CR or continue with treatment as usual (TAU). CR consisted of 10 weekly sessions with the therapist over 3 months, followed by four sessions over the next 6 months. Participants were reassessed after 3 and 9 months.
RESULTS
We included 475 participants, and 427 participants (90%) completed the trial (209 participants in the CR arm and 218 participants in the TAU arm). After 3 months, the ratings by both participants and carers in the CR group showed that participants were doing significantly better in relation to their goals, and this was maintained 6 months later. Ratings for the TAU-arm participants did not improve significantly. There were no other differences between the groups. There was a strong economic case for CR.
CONCLUSIONS
Cognitive rehabilitation is effective in enabling people with early-stage dementia to improve their everyday functioning in relation to individual goals targeted in the therapy sessions. Next steps will focus on the implementation of CR into NHS and social care services.

Autres résumés

Type: plain-language-summary (eng)
Cognitive rehabilitation (CR) is a personalised intervention to help people with early-stage dementia to manage everyday activities. This individualised therapy is conducted in people’s own homes over several sessions. A therapist works with the person and the carer to identify realistic and relevant goals, plan how to tackle these and support people in achieving them. Previous small studies suggested that CR could be beneficial.

Identifiants

pubmed: 30879470
doi: 10.3310/hta23100
pmc: PMC6441850
doi:

Banques de données

ISRCTN
['ISRCTN21027481']

Types de publication

Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-242

Subventions

Organisme : Department of Health
ID : 11/15/04
Pays : United Kingdom

Déclaration de conflit d'intérêts

Martin Knapp received funding from Lundbeck Limited (St Albans, UK) in relation to work on depression in younger adults and workplace mental health and from Takeda UK Limited (High Wycombe, UK) for advice on measures of the impact on carers of caring for people with dementia. Zoe Hoare is a member of the Health Services and Delivery Research Associate Board. Bob Woods received a grant from the Welsh Government via Health and Care Research Wales (Cardiff, UK).

Auteurs

Linda Clare (L)

Centre for Research in Ageing and Cognitive Health, University of Exeter, Exeter, UK.

Aleksandra Kudlicka (A)

Centre for Research in Ageing and Cognitive Health, University of Exeter, Exeter, UK.

Jan R Oyebode (JR)

School of Dementia Studies, University of Bradford, Bradford, UK.

Roy W Jones (RW)

Research Institute for the Care of Older People (RICE), Bath, UK.

Antony Bayer (A)

Division of Population Medicine, University Hospital Llandough, Cardiff University, Cardiff, UK.

Iracema Leroi (I)

Department of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.

Michael Kopelman (M)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, St Thomas' Hospital, King's College London, London, UK.

Ian A James (IA)

Centre of the Health of the Elderly, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.

Alison Culverwell (A)

Kent and Medway NHS and Social Care Partnership Trust, St Martin's Hospital, Canterbury, UK.

Jackie Pool (J)

Dementia Pal Ltd, Southampton, UK.

Andrew Brand (A)

North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK.

Catherine Henderson (C)

Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.

Zoe Hoare (Z)

North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK.

Martin Knapp (M)

Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.

Sarah Morgan-Trimmer (S)

Institute of Health Research, University of Exeter Medical School, Exeter, UK.

Alistair Burns (A)

Department of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.

Anne Corbett (A)

Centre for Research in Ageing and Cognitive Health, University of Exeter, Exeter, UK.

Rhiannon Whitaker (R)

Whitaker Research Ltd, Bangor, UK.

Bob Woods (B)

Dementia Services Development Centre, Bangor University, Bangor, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH